Terms: = Ovarian cancer AND HMGA2, HMGI-C, 8091, ENSG00000149948, LIPO, HMGIC, BABL AND Treatment
18 results:
1. Transformer 2β regulates the alternative splicing of cell cycle regulatory genes to promote the malignant phenotype of ovarian cancer.
Zhou T; Fu P; Chen D; Liu R
Oncol Res; 2023; 31(5):769-785. PubMed ID: 37547760
[TBL] [Abstract] [Full Text] [Related]
2. Role of M2-like macrophages in the progression of ovarian cancer.
Baek SH; Lee HW; Gangadaran P; Oh JM; Zhu L; Rajendran RL; Lee J; Ahn BC
Exp Cell Res; 2020 Oct; 395(2):112211. PubMed ID: 32755554
[TBL] [Abstract] [Full Text] [Related]
3. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract] [Full Text] [Related]
4. Tunneling Nanotubular Expressways for Ultrafast and Accurate M1 Macrophage Delivery of Anticancer Drugs to Metastatic ovarian Carcinoma.
Guo L; Zhang Y; Yang Z; Peng H; Wei R; Wang C; Feng M
ACS Nano; 2019 Feb; 13(2):1078-1096. PubMed ID: 30608136
[TBL] [Abstract] [Full Text] [Related]
5. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical liposomal Formulation for ovarian cancer treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract] [Full Text] [Related]
6. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular hmga2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract] [Full Text] [Related]
7. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract] [Full Text] [Related]
8. The oncogenic triangle of hmga2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family.
Busch B; Bley N; Müller S; Glaß M; Misiak D; Lederer M; Vetter M; Strauß HG; Thomssen C; Hüttelmaier S
Nucleic Acids Res; 2016 May; 44(8):3845-64. PubMed ID: 26917013
[TBL] [Abstract] [Full Text] [Related]
9. Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice.
Xu X; Ayub B; Liu Z; Serna VA; Qiang W; Liu Y; Hernando E; Zabludoff S; Kurita T; Kong B; Wei JJ
Mol Cancer Ther; 2014 Jul; 13(7):1729-39. PubMed ID: 24825857
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes with single agent lipo-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience.
Suprasert P; Manopunya M; Cheewakriangkrai C
Asian Pac J Cancer Prev; 2014; 15(3):1145-8. PubMed ID: 24606432
[TBL] [Abstract] [Full Text] [Related]
11. Effects of hmga2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells.
Xi YN; Xin XY; Ye HM
Asian Pac J Trop Med; 2014 Apr; 7(4):289-92. PubMed ID: 24507678
[TBL] [Abstract] [Full Text] [Related]
12. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract] [Full Text] [Related]
13. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
Hsiao SM; Chen CA; Lin HH; Hsieh CY; Wei LH
Gynecol Oncol; 2009 Jan; 112(1):35-9. PubMed ID: 18977021
[TBL] [Abstract] [Full Text] [Related]
14. liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.
Luo H; Zhong Q; Chen LJ; Qi XR; Fu AF; Yang HS; Yang F; Lin HG; Wei YQ; Zhao X
J Cancer Res Clin Oncol; 2008 Sep; 134(9):937-45. PubMed ID: 18350317
[TBL] [Abstract] [Full Text] [Related]
15. Pegylated liposomal doxorubicin (lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
[TBL] [Abstract] [Full Text] [Related]
16. Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review.
Hsieh CL; Chang TC; Lai CH; Jung SM; Chou HH
Gynecol Oncol; 2004 Sep; 94(3):854-7. PubMed ID: 15350389
[TBL] [Abstract] [Full Text] [Related]
17. Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo.
Sasaki H; Niimi S; Akiyama M; Tanaka T; Hazato A; Kurozumi S; Fukushima S; Fukushima M
Cancer Res; 1999 Aug; 59(16):3919-22. PubMed ID: 10463583
[TBL] [Abstract] [Full Text] [Related]
18. Prostaglandins in the treatment of cancer.
Sasaki H; Fukushima M
Anticancer Drugs; 1994 Apr; 5(2):131-8. PubMed ID: 8049495
[TBL] [Abstract] [Full Text] [Related]
